Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444433 | 0.92 | HRH3 (0.46) | HRH3SIGMAR1ALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL5445213 | 0.91 | NPY1R (0.45) | HRH3SIGMAR1ALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL5447266 | 0.90 | MEN1 (0.50) | HRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5332049 | 0.88 | HRH3 (0.42) | HRH3SIGMAR1ALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL5476485 | 0.85 | HRH3 (0.46) | HRH3SIGMAR1ALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL5455205 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAOBMAOA | |
| SCHEMBL5457594 | 0.81 | MAPT (0.49) | HRH3SIGMAR1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5448732 | 0.81 | PTPN7 (0.50) | SIGMAR1ALDH1A1MAOB | |
| SCHEMBL5453742 | 0.81 | MEN1 (0.49) | ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5460440 | 0.80 | HRH3 (0.42) | HRH3ALDH1A1SMN1; SMN2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HRH3 527/4885SIGMAR1 175/4885ALDH1A1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.